270 related articles for article (PubMed ID: 22227645)
1. Biotech entrepreneurs swoon over proposed fundraising changes.
Venkataramanan M
Nat Med; 2012 Jan; 18(1):3. PubMed ID: 22227645
[No Abstract] [Full Text] [Related]
2. Biotech boot camp.
Ledford H
Nature; 2015 Mar; 519(7544):402-5. PubMed ID: 25810186
[No Abstract] [Full Text] [Related]
3. Navigating biotechnology's new fiscal opportunities.
Purcell DJ
Nat Biotechnol; 1998 May; 16 Suppl():51-3. PubMed ID: 9591271
[No Abstract] [Full Text] [Related]
4. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
5. Spreading biotech dollars around Washington.
Senior M
Nat Biotechnol; 2013 Aug; 31(8):673-5. PubMed ID: 23929333
[No Abstract] [Full Text] [Related]
6. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
7. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
8. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
9. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
Reed SD; Califf RM; Schulman KA
Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
[TBL] [Abstract][Full Text] [Related]
10. Biotech booms in China.
Ellis S
Nature; 2018 Jan; 553(7688):S19-S22. PubMed ID: 29345681
[No Abstract] [Full Text] [Related]
11. Stelios Papadopoulos.
Papadopoulos S
Nat Biotechnol; 2011 Mar; 29(3):184. PubMed ID: 21390003
[No Abstract] [Full Text] [Related]
12. Protecting innovation in biotechnology startups.
Steffe EK; Shea TJ
Nat Biotechnol; 2003 Jul; 21 Suppl():BE51-3. PubMed ID: 12874982
[No Abstract] [Full Text] [Related]
13. Napster case spills into biotech sector.
Bouchie A
Nat Biotechnol; 2004 Sep; 22(9):1185-6. PubMed ID: 15384189
[No Abstract] [Full Text] [Related]
14. Q&A: Alan Auerbach on small and speedy biotechs. Interview by Eric Bender.
Auerbach A
Cancer Discov; 2012 Mar; 2(3):198. PubMed ID: 22585977
[No Abstract] [Full Text] [Related]
15. Path to approval proves rocky for copycat biodrugs.
Wadman M
Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004
[No Abstract] [Full Text] [Related]
16. FDA not NIH can speed new drugs.
Miller HI
Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
[No Abstract] [Full Text] [Related]
17. Sumitomo buys Oxford finance.
Bouchie A
Nat Biotechnol; 2004 Apr; 22(4):480. PubMed ID: 15085808
[No Abstract] [Full Text] [Related]
18. Japanese firms broaden investment focus to early biotech.
Louët S; Sipp D
Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
[No Abstract] [Full Text] [Related]
19. Growing pains for biopharmaceuticals.
Ashton G
Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
[No Abstract] [Full Text] [Related]
20. Biotech bonanza.
Stipp D
Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
[No Abstract] [Full Text] [Related]
[Next] [New Search]
